FDA-approved medication
Saxenda (liraglutide)
Key facts
Last reviewed: 2026-11-08- •FDA label says "SAXENDA (liraglutide) injection, for subcutaneous use".
- •FDA label says "Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm once daily at any time of day, without regard to the timing of meals."
- •FDA label says "SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition."
- •FDA label says "The recommended dose of SAXENDA is 3 mg daily. ( 2.2 ) • Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached."
FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.
liraglutide · 18 mg/3 mL (6 mg/mL) pre-filled pen · once daily, subcutaneous
- Active ingredient
- liraglutide
- Dosage form (label)
- Injection: 18 mg/3 mL (6 mg/mL) pre-filled pen
- Schedule (label)
- Once daily, subcutaneous
- Strengths (label)
- Injection: 18 mg/3 mL (6 mg/mL) solution in a pre-filled multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg. Injected subcutaneously once daily.DailyMed FDA Prescribing Information (NDA 206321) · Saxenda official website. Accessed November 8, 2026.
- Manufacturer
- Novo Nordisk A/S (per label)
Brand names are trademarks of their respective owners; this site is not affiliated with them.

FDA label
Saxenda dose steps (FDA label)
- 0.6 mgWeek 1Starting dose (daily)
- 1.2 mgWeek 2Dose escalation (daily)
- 1.8 mgWeek 3Dose escalation (daily)
- 2.4 mgWeek 4Dose escalation (daily)
- 3 mgWeek 5 onwardRecommended maintenance dosage
FDA label answers
Common questions about Saxenda
All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid 3946d389-0926-4f77-a708-0acb8153b143, SPL version 22, revised 06/2026)).
Who is Saxenda approved for?
FDA label says "SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition."
How often is Saxenda taken?
FDA label says "Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm once daily at any time of day, without regard to the timing of meals."
What are the most common side effects listed on the label for Saxenda?
FDA label says "Most common adverse reactions, reported in greater than or equal to 5% are: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis."
Is there a boxed warning on the Saxenda label?
Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice."
What is the recommended maintenance dose for Saxenda?
FDA label says "The recommended dose of SAXENDA is 3 mg daily. ( 2.2 ) • Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached."
Next Steps: Evaluating Saxenda for Your Care Plan
Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.
Out-of-Pocket Expense Modeling
Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.
Consultation & Lab Checklist
Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.
BMI Qualification & Directory
Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.
Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.
Before Starting Saxenda
Gradual Dose Titration
Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.
Lifestyle & Nutrition Support
In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.
Long-Term Plan
Talk with your clinician before changing or stopping treatment.
In-Depth Clinical Guides
Explore our clinical reviews, FDA label comparisons, and insurance navigation guides for Saxenda.
Comparing GLP-1 Medications
Daily liraglutide vs weekly semaglutide/tirzepatide mechanisms and efficacy.
BMI Criteria for GLP-1s
FDA-approved BMI thresholds and qualifying weight-related health conditions.
Gastrointestinal Tolerability
Practical strategies for managing nausea during daily titration.
Exploring non-injectable options?
Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.